Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants

Table 3 Median survival (mo) in study groups according to variables

	Total (n = 201)			Before 2008 (n = 127)			2008-2010 (n = 74)
	LFS	DFS	OS	LFS	DFS	OS	LFS	DFS	OS
Treatment protocols
Chemoradiotherapy	31.9	24.1	31.9	37.8	24.1	37.8	11.7	19.2	11.7
Chemotherapy	25.9	20.6	27.1	43.6	22.3	51.7	15.0	18.2	15.3
P value1	0.793	0.834	0.597	0.792	0.656	0.630	0.959	0.848	0.715
Chemotherapy protocolsa
FUFA	29.9	23.8	31.9
UFT	42.5	20.6	53.0
CEF	13.3	16.0	13.3
TCF	15.0	1.6	15.0
P value (FUFA-UFT)1	0.036	0.6	0.477
Surgical margin2
Positive	20.6	21.4	22.4	43.8	20.5	52.2	15.0	19.1	15.0
Negative	26.0	19.2	27.7	41.5	48.2	50.9	15.0	18.3	15.3
P value1	0.509	0.511	0.016	0.239	0.126	0.053	0.519	0.699	0.185
RT simulator planningb
2 dimensional	42.4	23.1	50.4
3 dimensional	14.1	16.0	14.1
P value3	NA	NA	NA
Time of RT initiation
< 4 mo	36.3	20.6	40.9
≥ 4 mo	39.8	16.8	39.8
P value	0.0581	NA	0.3704

¹Kaplan Meier-Log rank test;

²Based on patients on chemoradiotherapy;

³Not calculated to exclude potential bias since mean follow up duration was significantly longer in the 2 dimensional simulator planning group. Analysis was performed in the overall population, since

^aOnly 1 patient recevied FUFA in the “after 2008” group;

^b2-dimensional planning was the leading option before 2008 and 3 dimensional planning after 2008;

⁴Breslow test. FUFA: 5-fluorouracil and leucovorin-folinic acid; CEF: Cyclophosphamide, epirubicin, and fluorouracil; UFT: Uracil/tegafur; TCF: Docetaxel, cisplatin, and fluorouracil; RT: Radiation therapy; NA: Not available; OS: Overall survival; PFS: Progression-free survival; DFS: Disease-free survival.